IL-21 Induces Tumor Rejection by Specific CTL and IFN-γ-Dependent CXC Chemokines in Syngeneic Mice

Journal of Immunology

Volumn 172, Issue 3, 2004, Pages 1540-1547

  Di Carlo, Emma ^a   Comes, Alberto ^b   Orengo, Anna Maria ^b   Rosso, Ombretta ^b   Meazza, Raffaella ^c   Musiani, Piero ^a   Colombo, Mario P ^d   Ferrini, Silvano ^b,e  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ANTIBODY; CHEMOATTRACTANT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 21; MONOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRUS ENVELOPE PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CARCINOGENICITY; CELL DAMAGE; CELL INFILTRATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; ENDOTHELIUM CELL; FEMALE; GRAFT REJECTION; GRANULOCYTE; IMMUNITY; IMMUNOCOMPETENCE; IN VIVO STUDY; ISOGRAFT; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROVIRUS; T LYMPHOCYTE; TUMOR CELL; TUMOR REGRESSION; TUMOR REJECTION;

EID: 1642444178     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.3.1540     Document Type: Article

References (41)

1. Parmiani, G., M. P. Colombo, C. Melani, and F. Arienti. 1997. Cytokine gene transduction in the immunotherapy of cancer. Adv. Pharmacol. 40:259.
2. Musiani, P., A. Modesti, M. Giovarelli, F. Cavallo, M. P. Colombo, P. L. Lollini, and G. Forni. 1997. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today 18:32.
3. Lollini, P. L., and G. Forni. 1999. Specific and nonspecific immunity in the prevention of spontaneous tumours. Immunol. Today 20:347.
4. Parrish-Novak, J., S. R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J. A. Gross, J. Johnston, K. Madden, W. Xu, J. West, et al. 2000. Interleukin-21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57.
5. Ozaki, K., K. Kikly, D. Michalovich, P. R. Young, and W. J. Leonard. 2000. Cloning of a type I cytokine receptor most related to the IL-2 receptor β chain. Proc. Natl. Acad. Sci. USA 97:11439.
6. c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41:8725.
7. Asao, H., C. Okuyama, S. Kumaki, N. Ishii, S. Tsuchiya, D. Foster, and K. Sugamura. 2001. Cutting edge: the common γ chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167:1.
8. Kasaian, M. T., M. J. Whitters, L. L. Carter, L. D. Lowe, J. M. Jussif, B. Deng, K. A. Johnson, J. S. Witek, M. Senices, R. F. Konz, et al. 2002. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16:559.
9. Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al. 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin-15-deficient mice. J. Exp. Med. 191:771.
10. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669.
11. + T cells. J. Immunol. 169:5838.
12. Suto, A., H. Nakajima, K. Hirose, K. Suzuki, S. Kagami, Y. Seto, A. Hoshimoto, Y. Saito, D. C. Foster, and I. Iwamoto. 2002. Interleukin-21 prevents antigen-induced IgE production by inhibiting germ line Cε transcription of IL-4-stimulated B cells. Blood 100:4565.
13. Ozaki, K., R. Spolski, C. G. Feng, C. F. Qi, J. Cheng, A. Sher, H. C. Morse III, C. Liu, P. L. Schwartzberg, and W. J. Leonard. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630.
14. Wurster, A. L., V. L. Rodgers, A. R. Satoskar, M. J. Whitters, D. A. Young, M. Collins, and M. J. Grusby. 2002. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells. J. Exp. Med. 196:69.
15. Strengell, M., T. Sareneva, D. Foster, I. Julkunen, and S. Matikainen. 2002. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169:3600.
16. Di Carlo, E., R. Meazza, S. Basso, O. Rosso, A. Comes, A. Gaggero, P. Musiani, L. Santi, and S. Ferrini. 2000. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice. J. Pathol. 191:193.
17. Kimura, K., H. Nishimura, K. Hirose, T. Matsuguchi, Y. Nimura, and Y. Yoshikai. 1999. Immunogene therapy for murine fibrosarcoma using IL-15 gene with high translational efficiency. Eur. J. Immunol. 29:1532.
18. Meazza, R., P. L. Lollini, P. Nanni, C. De Giovanni, A. Gaggero, A. Comes, M. Cilli, E. Di Carlo, S. Ferrini, and P. Musiani. 2000. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential, and immune response. Im. J. Cancer 87:574.
19. Comes, A., E. Di Carlo, P. Musiani, O. Rosso, R. Meazza, C. Chiodoni, M. P. Colombo, and S. Ferrini. 2002. IFN-γ-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Eur. J. Immunol. 32:1914.
20. Nanni, P., C. De Giovanni, P. L. Lollini, G. Nicoletti, and G. Prodi. 1983. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1:373.
21. Dalton, D. K., S. Pittss-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259:1739.
22. Masson, P. J. 1929. Some histological methods: trichrome stainings and their preliminary technique. J. Tech. Methods 12:75.
23. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93:9730.
24. + myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur. J. Immunol. 33:19.
25. Gri, G., C. Chiodoni, E. Gallo, and M. P. Colombo. 2002. Antitumor effect of IL-12 in the absence of endogenous IFN-γ depends on tumor immunogenicity. Cancer Res. 62:4390.
26. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133.
27. Melero, I., G. Mazzolini, I. Narvaiza, C. Qian, L. Chen, and J. Prieto. 2001. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol. 22:113.
28. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFN-α affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25.
29. Cavallo, F., E. Di Carlo, M. Butera, R. Verrua, M. P. Colombo, P. Musiani, and G. Forni. 1999. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin-12. Cancer Res. 59:414.
30. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton. 1998. The CXC chemokines IP-10 and MIG are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161:927.
31. Di Carlo, E., G. Forni, P. L. Lollini, M. P. Colombo, A. Modesti, and P. Musiani. 2001. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97:339.
32. Carlos, T. M., and J. M. Harlan. 1994. Leukocyte-endothelial adhesion molecules. Blood 84:2068.
33. Strengell, M., S. Matikainen, J. Siren, A. Lehtonen, D. Foster, I. Julkunen, and T. Sareneva. 2003. IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol. 170:5464.
34. Ugai, S., O. Shimozato, K. Kawamura, Y. Q. Wang, T. Yamaguchi, H. Saisho, S. Sakiyama, and M. Tagawa. 2003. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 10:187.
35. Mohan, K., Z. Ding, J. Hanly, and T. B. Issekutz. 2002. IFN-γ-inducible T cell α chemoattractant is a potent stimulator of normal human blood T lymphocyte transendothelial migration: differential regulation by IFN-γ and TNF-α. J. Immunol. 168:6420.
36. Cole, K. E., C. A. Strick, T. J. Paradis, K. T. Ogborne, M. Loetscher, R. P. Gladue, W. Lin, J. G. Boyd, B. Moser, D. E. Wood, et al. 1998. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187:2009.
37. Kobayashi, H., S. Koga, A. C. Novick, H. Toma, and R. L. Fairchild. 2003. T-cell mediated induction of allogenic endothelial cell chemokine expression. Transplantation 75:529.
38. Romagnani, P., F. Annunziato, L. Lasagni, E. Lazzeri, C. Beltrame, M. Francalanci, M. Uguccioni, G. Galli, L. Cosmi, L. Maurenzig, et al. 2001. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 107:53.
39. Ma, H. L., M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, and K. Dunussi-Joannopoulos. 2003. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J. Immunol. 171:608.
40. Colombo, M. P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52:4853.
41. Cavallo, F., P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M. J. Brunda, M. P. Colombo, and G. Forni. 1997. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89:1049.